| Name | Title | Contact Details |
|---|
Arminco Inc. is the premier provider of dental design, construction, project management, and equipment sales & service. Projects are overseen by a full-service, in-house team of financial experts, designers, architects, contractors and equipment specialists. Projects include pediatric and orthodontics, surgical and other medical offices, veterinary practices as well as restaurants, churches, nail boutiques and other high end establishments. Founded in 1996, Arminco Inc. has grown from a small family business to a 50+ employee, multi-million dollar company operating throughout the US.
LFI specializes in the sale and service of contemporary furnishings to public, private, school, and academic libraries. By meeting the rapidly changing sociological and technological changes through design and product, LFI has become the Midwests leading library furnishing company.
Axolight is a lighting company, based in Italy and the United States, which designs and produces high-end decorative design lamps. Handmade in Italy Each Axolight product, whether it derives from mass production or from a customized request, is designed, developed, tested and assembled by hand at the company workshop in Venice - Scorzè.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
IHP offers health plan options to companies across the country, with the goal of providing affordable healthcare with a clear, and distinct, schedule of benefits. Our plans are guaranteed issue, zero deductible, and co-pay driven—well change the way you think about healthcare.